Dapagliflozin for Heart Failure

"AstraZeneca spearheaded the inaugural clinical trial for Dapagliflozin in 2014, which included 700 participants. After gaining N/A approval that same year, 63 active studies are now taking place globally across 235 cities and 50 nations."

"Given that this is a phase 2 study, with data in support of safety but not efficacy, our team at Power gave Dapagliflozin a score of 2."

"When treating pharmaceutical preparations, dapagliflozin is often the medication of choice. It can also be a viable solution for patients who have tried dieting and exercising with minimal success or those not responding to single therapy."

"Indeed, the information available on clinicaltrials.gov attests to this trial's ongoing recruitment efforts; it was first posted in February 2021 and has most recently been updated in March 2022. At present, 46 participants are needed from a single medical site."

"Affirmative. Clinicaltrials.gov provides evidence that the clinical trial is still recruiting, which began on February 24th 2021 and was last modified on March 23rd 2022. A total of 46 patients will be accepted at one site for enrollment into this study."